Molecular Pharmacology
- Bachelor projects Molecular Pharmacology
- Master projects Molecular Pharmacology
- Pharmacology of Chronic Diseases and Aging
- MG: Endocrine system, Respiratory tract and Digestive Tract
- MG: Circulatory Tract- Collected Medicine Groups
- Academic research and communication skills (1, 2 and 3)

A/Prof. Job van Boven is a real-world drug outcomes expert specialised in lung diseases. He is the founding director of the Medication Adherence Expertise Center Of the northern Netherlands (MAECON) and Chair of the European Commission funded European Network to Advance Best Practices & Technology on Medication Adherence (ENABLE) COST Action, comprising 40 countries. He leads the research group on Cost-effective Drug Use (in Dutch: Doelmatig Geneesmiddelgebruik) at the Department of Clinical Pharmacy & Pharmacology of the University Medical Center Groningen and is Principal Investigator at the Groningen Research Institute for Asthma and COPD (GRIAC) and Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET) group of the UMCG.
He obtained his PharmD and PhD at the University of Groningen (The Netherlands), where his thesis focused on the cost-effectiveness of adherence enhancing interventions in patients with Chronic Obstructive Pulmonary Disease (COPD). After his PhD research, he completed fellowships at the University of Colorado (USA), Monash University (Australia) and the Hospital Universitario Son Espases (Spain).
He is (co)author of >175 scientific publications (H-index: 39), supervisor of 10 PhD students and received several research prices & grants (totalling>€6 million). He is Chair of the European Respiratory Society CRC on digital respiratory health "CONNECT", Chair of the Dutch respiratory pharmacists group (KNMP SIG Long), former Boardmember of the Dutch young Medicines Evaluation Board (Jong CBG), ZonMW-GGG committee member, Scientific lead of the Lung Alliance Netherlands (LAN) National Medication Adherence Program, expert research faculty at the IPCRG & EAACI, Editorial Board member of various peer-reviewed journals and has an extensive international network (e.g. ERS, IPCRG, EAACI, ISPE, REG, ESPACOMP, ISPOR).
Having interest and wide experience in both medication adherence and health economic methods, his mission is to find novel, cost-effective ways to make better, personalized use of our respiratory medications in order to maximize both patients’ and societal benefits.
Through multidisciplinary research, education and care support, he aims to provide means to accelerate implementation of drug-device technologies (digital inhalers, electronic pill bottles & blisters and smart spacers) and practical adherence monitoring & management tools (e.g. the TAI Toolkit) in daily clinical practice, to ultimately optimize patient, economic and societal outcomes.

Specialties:
- Methods & application: medication adherence, compliance, persistence, e-health, smart inhalers, bottles and spacers, digital adherence technology, (pharmaco) epidemiology, real-world drug outcomes, pharmacoeconomics, health economics, burden of disease, budget impact, health technology assessment, cost-effectiveness.
- Disease focus areas: Asthma / COPD / TB / CF/ Lung cancer  

I am pulmonologist at the University Medical Center Groningen, The Netherlands. I am one of the medical doctors of the Home Mechanical Ventilation Center Groningen, part of the department of pulmonary diseases of this hospital. Next to clinical work, I educate medical students from the University Groningen and have a strong connection with the University Twente, one of the main technical universities, both for educational activities and research. My main research interests involves severe COPD, respiratory failure, and (home) mechanical ventilation. I have special interest in remote monitoring and care to facilitate complex care at home. A second field of interest concerns nasal high flow therapy, in current COVID-19 times but also in the treatment of stable and post-exacerbation COPD. Furthermore, I have special interest in optimal but non-invasive and robust monitoring during long-term non-invasive ventilation and the application of more detailed monitoring facilities such as respiratory EMG, patient-ventilator asynchrony and lung mechanics during long-term non-invasive ventilation. My final goal is to achieve a better quality of life for patients with respiratory failure. To this end, we will need further studies on more and better treatment options investigating underlying mechanisms on severe COPD and how treatment affects these.

Reinoud Gosens (1977) is Professor in Translational Pharmacology at the Faculty of Science and Engineering of the University of Groningen. He obtained his PhD in pharmacology in 2004 at the University of Groningen and performed postdoctoral studies at the University of Manitoba, Canada until 2007. His research is focused on the mechanisms that regulate tissue repair and remodeling in asthma and COPD. In particular, the role and therapeutic potential of muscarinic receptors and Wnt/Frizzled receptor signaling  in tissue repair and remodeling are studied.

Experimental lungpathology, immunology, epigenetics, mouse models for asthma and COPD, lungtissue regeneration

COPD and astma

Macrophage biology
Data science
Immunology
Lung pathology
Pulmonology
Microplastics
Animal models of asthma, COPD, and pulmonary fibrosis
Flow cytometry
Histology

Ik ben opgeleid als wetenschappelijk onderzoeker met een sterke focus op cellulair en moleculair immunologisch onderzoek, waarbij ik een steeds sterkere interesse heb ontwikkeld in het doen van translationeel onderzoek in een multidisciplinaire setting. Mijn unieke expertise is het ontwikkelen van experimentele en preklinische modellen waarin mechanismes van complexe ziektes van het ademhalingsstelsel worden onderzocht, met als doel nieuwe interventies te ontwikkelen gebaseerd op de persoonlijke aanleg voor de aandoening. Naast het wetenschappelijk onderzoek draag ik met veel plezier bij aan het Geneeskunde en Immunologie onderwijs binnen het UMCG en de Rijksuniversiteit Groningen. Ik ben als Immunoloog erkend volgens de SMBWO criteria.

Mijn onderzoek kent twee thema’s, die allebei een sterk translationeel karakter hebben:Ten eerste heb ik een onderzoekslijn functionele genetica van chronische longaandoeningen , waarbinnen wij de biologische effecten proberen te ontrafelen van de genetische variatie die bijdraagt aan de gevoeligheid van de patiënt voor astma of COPD.  Ten tweede heb ik een onderzoekslijn translationeel onderzoek naar de mechanismen van allergeen immunotherapie , waarbinnen we in een combinatie van basaal onderzoek in muismodellen en patient-gebonden onderzoek het werkingsmechanisme van allergeen immunotherapie proberen te achterhalen, met als doel de effectiviteit van deze behandeling te kunnen verbeteren.

Professor Oudkerk is professor of Radiology at the University of Groningen, Chief Scientific Officer of the Institute for Diagnostic Accuracy- iDNA (formerly of the Center of Medical Imaging Norht East Netherlands (CMI-NEN) , NWO research Center of Exellence) and the principal investigator for Radiology of the NELSON lung cancer detection study. Founder and past president of the European Society of Cardiac Radiology and former Chairman of Radiology departments of DDHK Erasmus MC Rotterdam and University Medical Center Groningen. Prof. Oudkerk has a broad insight into new imaging modalities, algorithms and strategies. He is ranked as one the most influential researchers in Radiology in Europe (2019). For his research work he received prestigious grants such as ERC advanced grant, Royal Academy of Sciences of the Netherlands (KNAW), Ministry of Science and Technology of China, NWO, KWF, NKB grants etc.He is lead investigator of the NELSON lungcancer detection study, the ROBINSCA study for coronary disease detection, NELCIN B3 study in China focusing on Lungcancer , coronary artery disease and pulmonary disease  in one imaging test. Many of the current and new guidelines are derived from his original work. For example- Diagnostic management strategies for pulmonary embolism, lungcancer screening, imaging of the myocardial ischaemic cascade etc-furthermore the introduction of High Power Gradient Magnetic Resonance Imaging and body MRI in Europe- Introduction of the first continuous rotating spiral computed tomography scanner. Prof. Oudkerk was invited as a member of the medical advisory board of Siemens AG, Germany for development of the first continuous rotating spiral CT and has been part of this board until the development of the current volume multi-detector CT scanners pushing forward the need for higher temporal resolutions in CT scanning comparable with EBT. With his researchteam he initiated the field of CT coronary imaging; / EBT coronary angiography- use of volume rendering for cardiac CT- fly-through coronary arteries on CT (CT angioscopy)- MDCT coronary angiography- 4D MDCT coronary visualization- MDCT thrombus detection in ACS- and he initiated in the field of CT lung cancer screening new management strategies for early lung cancer detection of the prospective multi-center lung cancer screening study (NELSON) since 2000. Other research activities are non-invasive testing of coronary atherosclerosis ( by- passing more than 20 indirect tests), imaging of  liver metastasis, coronary calcium scoring, vena cava stenting, MR infarct imaging, CT recognition of acute aortic dissection, infusion rate of contrast agents in small bowel imaging /, as well as the concept of high power gradient body MR generating many spin-off scientific publications. He has an influential vision on the future of imaging and health care, which has been rewarded with international awards and invitations to lecture on (inter-)national platforms Prof. Oudkerk has achieved to independently receive external financing for several research projects.  Cooperation with international partners throughout the world (among others, England, Poland, USA, China) in multidisciplinary multi-center studies. Prof. Oudkerk is inspiring many (inter-)national students to start their PhD research in his department, resulting in several PhD defenses per year.Prof Oudkerk published more than 555 peer reviewed articles, is cited over 20,000 times with an H-index >70 (Scopus June 2019). Key publications in NEJM, Lancet, Thorax, Circulation, JACC, Eur Heart, Radiology, Lancet Oncology, etc.

The translational research focuses on the molecular pharmacological aspects of the development and course of chronic inflammatory diseases. Our motivation for this research focus is very personal, we truly believe that research in the field of translational pharmacology is clustered around molecular partners in defined subcellular compartments (signalosomes) that enables cells to exert highly specialized tasks. Devastating diseases, e.g. cancer, type-II diabetes mellitus, Alzheimers’s dementia, heart failure, asthma, COPD, and infection diseases are associated with defective or derailed signaling processes, and research into the control of these processes clearly is of great public and social importance as well. Currently our research focus lies on chronic inflammatory disorders, and I focus nowadays on experimental models of COPD and related lung disorders, Alzheimer, Parkinson and microbial infections. We successfully undertaken the effort to link the themes to defined subcellular compartments (signalosomes). We linked  novel signaling pathways from membrane receptors towards the recently identified PLC-e isoform, the cAMP sensor Epac. I defined novel and exciting functions of the cytoskeleton driver cofilin, a signal node clearly linked to microbe invasion. I linked this novel clusters to inflammation, remodeling next to the repair of the epithelial barrier and epithelial-to-mesenchymal transition as a mechanism driving fibrosis.

Pulmonary pathology

Nutrition & Asthma

Regenerative Pharmacology

Bioinformatics, biostatistics